COMP <GO>
SGHT vs ANGO // REVENUE GROWTH (YOY)
Sight Sciences Inc. (NASDAQ) VS. AngioDynamics Inc. (NASDAQ) • 15-METRIC TALLY: SGHT 4
— ANGO 6
▲ REVENUE GROWTH (YOY) LEADER: ANGO
LAST: $9.57 (+3.57%) • MKT CAP: $527.2M
revenue-growth
-3.10%
LAST: $12.35 (+1.81%) • MKT CAP: $519.4M
revenue-growth
9.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SGHT VS. ANGO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SGHT | ANGO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 86.20% | 54.60% | +31.60 | SGHT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -23.40% | -11.60 | ANGO | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -5.67% | 0.10% | -5.77 | ANGO | /fcf-yield <GO> |
| Operating Margin | -48.00% | -12.50% | -35.50 | ANGO | /operating-margins <GO> |
| Net Profit Margin | -49.70% | -11.50% | -38.20 | ANGO | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | -3.10% | 9.50% | -12.60 | ANGO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.16 | 2.12 | +0.04 | SGHT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 6/9 | -1.00 | ANGO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.3 | 39.4 | +19.89 | SGHT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $527.2M | $519.4M | $7.8M | SGHT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SGHT REV | ANGO REV | SGHT GROSS % | ANGO GROSS % | SGHT FCF | ANGO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $77.4M | $320.2M | 86.2% | 54.6% | -$29.9M | $508.0K |
| FY 2024 | $79.9M | $292.5M | 85.5% | 53.9% | -$22.7M | -$14.6M |
| FY 2023 | $81.1M | $303.9M | — | — | -$47.2M | -$28.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SGHT // BETA —
ANGO // BETA —